Digital Biomarkers Market to Grow with a CAGR of 14.88% through 2030

Failure of drugs for neurodegenerative disorders and investment in voice-based digital biomarkers is expected to drive the Global Digital Biomarkers Market growth in the forecast period, 2026-2030.

According to TechSci Research report, “Digital Biomarkers Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Digital Biomarkers Market stood at USD 3.49 billion in 2024 and is anticipated to grow with a CAGR of 14.88% in the forecast period. With the increasing adoption of recent advancements and remote technologies, the market for digital biomarkers is expected to witness significant growth during the forecast period.

The expansion of remote data collecting technologies, the largest segment within the digital biomarkers market, has been driven by advancements in wearable and mobile technology. Furthermore, the growing utilization of the internet has further contributed to the progress of this market segment.

Preventive healthcare is garnering increasing interest and attention as patients and healthcare professionals recognize the importance of early disease identification and avoidance. Digital biomarkers have proven to be valuable in this realm, by detecting early illness symptoms and enabling targeted therapies. The advancements in artificial intelligence and machine learning have facilitated the creation of sophisticated algorithms capable of analyzing vast amounts of data and identifying emerging patterns. This surge in demand for precise and reliable digital biomarkers has consequently driven market growth.

Digital biomarkers fulfill the patients' need for regular health assessments, offering affordable and personalized treatment to ensure optimal patient care. The rapid expansion of telecommunications and IT infrastructure, coupled with the growing utilization of advanced digital devices, has further fueled the market growth of digital biomarkers. In response to the severe impact of the Covid-19 outbreak, regulatory entities have expressed interest in developing digital biomarker-based medications. 

The evolving technologies are propelling businesses to produce a diverse range of digital biomarkers, which is expected to contribute to market growth in the coming years. Many companies are capitalizing on the increasing acceptance of data and devices by generating digital biomarkers. A notable example is the CDC's finding that warnings for Atrial Fibrillation through a specific wristwatch matched a genuine ECG 84% of the time, effectively reducing the risk of mortality. The popularity of smartwatches and consumer wearables that monitor various physiological aspects of the human body is on the rise.

Furthermore, the market participants' introduction of innovative and user-friendly wearables for monitoring vital signs has also boosted the demand for digital biomarkers. For instance, Shimmer Research introduced the Verisense Digital Health Panel (DHP) in November 2022, providing medical researchers with access to unprocessed, real-world sensor data for digital health. While the potential of digital biomarkers is increasingly recognized, there is a need for more precise legislative guidelines regarding their development and usage. Companies may face challenges navigating the regulatory landscape and obtaining product authorization, which could hinder market growth in the forecast period.

The global digital biomarkers market is driven by the expanding applications in areas such as diabetes, respiratory diseases, cardiovascular diseases (CVDs), and sleep disorders. Increased investments in drug research and development have led to higher drug costs. Moreover, the growing prevalence of chronic diseases and the aging population worldwide are fueling the demand for digital biomarkers. The elderly are particularly susceptible to chronic diseases. The proliferation of digital technologies, including handheld and wearable devices, has contributed significantly to the digital biomarkers market. The increasing use of health informatics in the healthcare industry is also fostering the growth of the global digital biomarkers market.

Digital biomarkers serve the essential purpose of enabling patients to monitor their health conditions regularly and seek consultations as needed. They offer cost-effective and personalized treatment to ensure effective patient care. Additionally, the rapid development of telecommunications and IT infrastructure, along with government and corporate investments in healthcare digitalization and smart hospitals, is expected to further drive the demand for digital biomarkers globally in the foreseeable future.                                                                               

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Digital Biomarkers Market”

The Global Digital Biomarkers Market is segmented into component, type, therapeutic area, end user, regional distribution, and company.

Based on the therapeutic area, the cardiovascular diseases segment has emerged as the dominant force in the global digital biomarkers market in 2024, both in terms of revenue and market share. This dominance is expected to continue throughout the forecast period. The primary factor driving this trend is the alarming rise in the prevalence of cardiovascular diseases among the global population. According to the World Health Organization, cardiovascular diseases are responsible for approximately 32% of all global deaths, making it the leading cause of mortality worldwide. The increasing prevalence of cardiovascular diseases can be attributed to a multitude of factors, including the rising consumption of tobacco, unhealthy food habits, and smoking. These lifestyle choices have contributed to a significant surge in the number of individuals affected by cardiovascular ailments. As a result, the demand for digital biomarkers tailored to monitor and manage cardiovascular conditions has witnessed a substantial upswing. In 2024, the cardiovascular diseases segment accounted for the largest market share in the global digital biomarkers market. These innovative digital tools capture and analyze patients' data, leading to improved patient care and treatment outcomes. By leveraging advanced technologies, such as artificial intelligence and machine learning, digital biomarkers have the potential to revolutionize the field of cardiovascular healthcare. Looking ahead, the cardiovascular diseases segment is poised for further growth and expansion in the forthcoming years. The continuous advancements in digital biomarkers, coupled with the increasing adoption of remote patient monitoring, are expected to fuel the growth of this segment. The integration of digital biomarkers into the healthcare ecosystem holds immense promise in enabling early detection, prevention, and personalized treatment strategies for cardiovascular diseases.

Based on region, North America segment is expected to grow during the forecast period. North America is projected to showcase dominance in the digital biomarkers market due to several factors. These include the increasing prevalence of chronic diseases, the substantial number of clinical trials conducted in the United States, and the availability of technologically advanced products in the region. Furthermore, the market in North America is witnessing a surge in demand for digital biomarkers due to the continuous technological advancements by market players and the presence of key industry players in the region. 

Major companies operating in Global Digital Biomarkers Market are:

• ActiGraph, LLC
• AliveCor, Inc.
• Altoida AG
• Biogen Inc.
• Fitbit, Inc.
• HumanAPI Inc.
• Pfizer, Inc.
• Sanofi S.A.
• Novartis International AG
• Neurotrack Technologies, Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The growing utilization of digital biomarkers across various applications, such as diabetes, respiratory diseases, cardiovascular diseases (CVDs), and sleep disorders, is driving significant growth in the global digital biomarkers market. Increased investments in drug research and development have led to higher drug costs. Moreover, the rising prevalence of chronic diseases and the expanding geriatric population worldwide are fueling the demand for digital biomarkers, particularly among older individuals who are more susceptible to such conditions. The widespread adoption of handheld and wearable digital devices, facilitated by the proliferation of digital technologies, plays a crucial role in the digital biomarkers market. Additionally, the increasing utilization of health informatics in the healthcare industry is fostering the expansion of the global digital biomarkers market”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Digital Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component (Data Collection Tools {Digital Platforms, Mobile Apps, Desktop-Based Software, Wearable, Others} v/s Data Integration Systems), By Type (Novel Digital Biomarkers, Original Digital Biomarkers, Approved Digital Biomarkers), By Therapeutic Area (Cardiovascular Diseases, Sleep & Movement Diseases, Neurodegenerative Disorders, Psychiatric Disorder, Others), By End User (Biotechnology & Pharmaceutical Companies, Payers, Providers, Others), By Region and Competition 2020-2030F”, has evaluated the future growth potential of Global Digital Biomarkers Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Digital Biomarkers Market.

Contact

Techsci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

M: +13322586602

Email: [email protected]

Website: https://www.techsciresearch.com